Is Aytu Biopharma, Inc. overvalued or undervalued?

As of 10 September 2025, the valuation grade for Aytu Biopharma, Inc. moved from expensive to fair. The company is currently fairly valued based on its metrics. The P/E ratio stands at 2, the Price to Book Value is 0.35, and the EV to EBITDA ratio is 2.23, indicating a low valuation relative to earnings and book value.
In comparison to its peers, Aytu Biopharma has a P/E ratio of 2.4637, while Eiger BioPharmaceuticals, Inc. and Biofrontera, Inc. show negative P/E ratios, suggesting that Aytu is in a better position among its risky counterparts. The company's stock has outperformed the S&P 500 over the past week and month, with returns of 3.04% and 7.73%, respectively, although it has lagged behind the index over the longer term, particularly in the 3-year and 5-year periods.